Payers begin to make plans for coming wave of biosimilars.
Carroll
John
J
JCarroll@ManagedCareMag.com
D001685:Biological Factors / Q000191:economics*; D017277:Drug Approval / Q000191:economics* / Q000331:legislation & jurisprudence; D018166:Health Care Reform / Q000191:economics / Q000331:legislation & jurisprudence*; D006801:Humans; D007349:Insurance, Health, Reimbursement / Q000191:economics*; D007880:Legislation, Drug / Q000191:economics*; D014481:United States
D001685:Biological Factors